SCHEMBL6595468

SCHEMBL6595468

CC(C)(C)OC(=O)Nc1cnccc1CCN1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.42
BACE1 P56817 1/20 0.42
DRD2 P14416 1/20 0.41
CYP17A1 P05093 2/20 0.40
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
NAMPT P43490 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CD274 Q9NZQ7 1/20 0.37
NR1I3 Q14994 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
GPR119 Q8TDV5 3/20 0.37
PDE5A O76074 1/20 0.37
PDE4A P27815 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627397 0.94 ACHE (0.39) ACHEBACE1DRD2CYP17A1PDE5A
SCHEMBL6035419 0.93 ACHE (0.46) ACHEBACE1DRD2CYP17A1NAMPT
SCHEMBL6595160 0.83 GPR119 (0.34) ACHEBACE1NAMPTCYP3A4GPR119
SCHEMBL6604898 0.83 CCNE2 (0.45) ACHEBACE1CYP17A1NAMPTPDE5A
SCHEMBL6035089 0.82 HRH3 (0.45) DRD2TDP1L3MBTL1HRH3NAMPT
SCHEMBL12018154 0.80 CYP17A1 (0.48) CYP17A1NAMPTCYP3A4
SCHEMBL30601022 0.80 CYP17A1 (0.48) CYP17A1NAMPTCYP3A4
SCHEMBL8209502 0.80 CYP17A1 (0.43) CYP17A1NAMPTCYP3A4
SCHEMBL23970808 0.77 CYP17A1 (0.45) CYP17A1NAMPTGPR119
SCHEMBL30411576 0.77 CYP17A1 (0.45) CYP17A1NAMPTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 EP disclosed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 WO disclosed